-
02/05/2024
Unveiling the Future: Highlights from the FDA/MDIC Symposium on Computational Modeling and Simulation (CM&S) in Washington D.C.
The FDA/MDIC Symposium on Computational Modeling and Simulation (CM&S) in Washington DC (April 15-17, 2024) unfolded its vibrant tapestry for three enlightening days of interdisciplinary innovation and collaboration.
-Read more-
-
30/04/2024
Council releases Draft Conclusions on Horizon 2020 evaluation
The Council of the European Union highlighted the significance of Horizon 2020 in bolstering the EU's competitiveness in its Draft Conclusions regarding the ex-post evaluation of the research and innovation funding program.
-Read more-
-
30/04/2024
WHO introduces cutting-edge digital health advocate utilizing generative AI for public health
The World Health Organization (WHO) announces the debut of S.A.R.A.H., a prototype digital health advocate equipped with an enhanced empathetic interface driven by generative artificial intelligence (AI).
-Read more-
-
30/04/2024
EFPIA advocates for responsible AI use in medicine development
The European Federation of Pharmaceutical Industries and Associations (EFPIA) underlines the potential benefits of employing Artificial Intelligence (AI) in advancing patient care, fostering innovation, and benefiting society at large.
-Read more-
-
30/04/2024
European Parliament approves EHDS
On 24 April 2024, the European Parliament endorsed the provisional agreement on the European Health Data Space (EHDS) reached between the Parliament and the Council.
-Read more-
-
30/04/2024
In the literature: April 2024 highlights
Click here to read some interesting recently published papers from our community. If you have published an article in the field of in silico medicine, send it to us: we will include it in this section of the newsletter!
-Read more-
-
23/04/2024
PhD and postdoc opportunities - April 2024
New calls with deadlines end May-early June
-Read more-
-
22/04/2024
In silico trial predict phase 3 clinical trial result
Dr. Duruisseaux from the Hospice Civil de Lyon (France) prospectively replicated a three-year long phase 3 trial (FLAURA 2) with an in silico trial executed on 5000 virtual patients, in few weeks. Days before the official release of the phase 3 FLAURA 2 results, he posted the promising results of the in-silico prediction on X, formerly Twitter, which closely resembled the real-clinical trials, albeit at fraction of time and cost.
-Read more-